Prakash Agarwal, Equity Analyst - India Pharma, RBS is positive on Lupin and advises investor to buy on dips. In the largecap space, Cipla is his top pick He has a target price of Rs 371 on the stock. In the midcap space, he likes Glenmark Pharma.
first published: Jul 7, 2011 02:04 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Pulls Back After Reclaiming 25,800 Even As Banks & IT Shine; All Eyes On RIL Q3| Closing Bell Live
Trump Warns Iran at UN: 'All Options on the Table' as Protests Rage
Iran Erupts — But the Opposition Is Tearing Itself Apart | Opposition Divided as Iran Burns
Nifty Likely To Tread Water After Back-To-Back Losses; RIL, Infosys In Focus| Opening Bell Live
